Pages that link to "Q26865789"

The following pages link to PD-1 as an emerging therapeutic target in renal cell carcinoma: current evidence (Q26865789):

Displaying 19 items.

• Targeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinoma (Q26775769) (← links)
• PD-1 and its ligands are important immune checkpoints in cancer (Q28069485) (← links)
• Novel immunotherapy in metastatic renal cell carcinoma (Q33863074) (← links)
• PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation (Q34996125) (← links)
• T-cell exhaustion in the tumor microenvironment (Q36347369) (← links)
• Personalized Oncology Meets Immunology: The Path toward Precision Immunotherapy (Q37059928) (← links)
• Core-shell nanoscale coordination polymers combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy (Q37191649) (← links)
• The head and neck cancer immune landscape and its immunotherapeutic implications (Q37351606) (← links)
• Overview and management of toxicities associated with systemic therapies for advanced renal cell carcinoma (Q38583235) (← links)
• Recent advances in renal cell carcinoma from a pathological point of view. (Q38909760) (← links)
• Recent Advances in the Medical Treatment of Recurrent or Metastatic Renal Cell Cancer (Q39044249) (← links)
• Pembrolizumab: first experience with recurrent primary central nervous system (CNS) tumors (Q39632681) (← links)
• Targeted alpha therapy using a novel CD70 targeted thorium-227 conjugate in in vitro and in vivo models of renal cell carcinoma (Q41346916) (← links)
• Autophagy inhibition upregulates CD4+ tumor infiltrating lymphocyte expression via miR-155 regulation and TRAIL activation (Q41914210) (← links)
• Immune checkpoint inhibitors in cancer therapy (Q45871487) (← links)
• Clinicopathologic Analysis of PD-L1 and PD-L2 Expression in Renal Cell Carcinoma: Association with Oncogenic Proteins Status. (Q54240564) (← links)
• Clinical significance of programmed death-1 and programmed death-ligand 1 expression in the tumor microenvironment of clear cell renal cell carcinoma. (Q64963592) (← links)
• Current Perspectives in Cancer Immunotherapy (Q90419584) (← links)
• Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial (Q91958139) (← links)